Holen Sie sich die Stockscreener-App
2.35
1.27%
-0.010
Schlusskurs vom Vortag:
$2.36
Offen:
$2.34
24-Stunden-Volumen:
1,193
Relative Volume:
0.02
Marktkapitalisierung:
$19.39M
Einnahmen:
$2.00M
Nettoeinkommen (Verlust:
$-11.43M
KGV:
-1.2008
EPS:
-1.957
Netto-Cashflow:
$-10.05M
1W Leistung:
-1.06%
1M Leistung:
+9.39%
6M Leistung:
-70.43%
1J Leistung:
-18.67%
1-Tages-Spanne:
$2.34
$2.3525
1-Wochen-Bereich:
$2.32
$2.50
52-Wochen-Spanne:
$1.81
$12.37
Lipocine Inc Stock (LPCN) Company Profile
Firmenname
Lipocine Inc
Sektor
Branche
Telefon
801 994 7383
Adresse
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.3525 | 19.46M | 2.00M | -11.43M | -10.05M | -1.957 |
VRTX
Vertex Pharmaceuticals Inc
|
522.57 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.98 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.41 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.62 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
208.90 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-06-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-11 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
| 2015-06-23 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
Lipocine Stock Price Forecast. Should You Buy LPCN? - StockInvest.us
Lipocine Inc (NASDAQ: LPCN) Share Price, LPCN Stock News, LPCN Share Price & Updates - Kalkine
Lipocine (LPCN) Advances 3.06% to $2.35, Testing Key Resistance ZoneSeasonality Effect - vinanet.vn
Lipocine (LPCN) Jumps 5.35% to $2.27 as Buyers Target $2.38 ResistanceTRIN Signal - vinanet.vn
Lipocine (LPCN) Q2 2026 Results: The Bottom-Line Figure Beats Its Comparison for the Current Session; After Results: The Share Price Moves Only Slightly under the Current SnapshotGross Profit Margin - vinanet.vn
Lipocine (LPCN) adds Grissinger to pay panel at $7,500 a year - Stock Titan
Lipocine (LPCN) Q2 2026 Scorecard: EPS Comes in Above Forecast in Latest Trading; Price Reaction - vinanet.vn
Lipocine (LPCN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations in Latest Trading; Immediate Response: The Stock Ends Down 0.49% in the Current UpdateEarnings Preview - dars.gov.et
Lipocine Inc. (LPCN) Edges Higher to $2.12, Holding Above Key SupportAdvance Decline Volume - dars.gov.et
Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake - Stock Titan
LPCN Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus as Revenue Remains Absent - vinanet.vn
Weekly Recap: Q2 revenue drop and Brilzio partner search - TradingView
LPCN Q2 2026 Earnings: Loss Narrower Than Expected, Shares Ease 1.41%Earnings Turnaround - vinanet.vn
Lipocine Inc. (NASDAQ: LPCN) awards director 2,000 stock options - Stock Titan
Lipocine Inc. (LPCN) director Grissinger files initial ownership statement - Stock Titan
Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Lipocine files Form 3 initial beneficial ownership statement for director Michael Grissinger - Bitget
Lipocine Inc (LPCN) Stock News Today - TradingKey
LPCN Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage SpendingMargin Improvement Report - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Lipocine (LPCN) and High Tide (HITI) - The Globe and Mail
Lipocine (LPCN) Slips 1.8% to $2.13 as Biotech Stock Holds Above Key $2.02 SupportVWAP Breakout - dars.gov.et
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Lipocine Inc (LPCN) Earnings Date & Reports & Earnings News - TradingKey
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 - Morningstar
Lipocine Q2 net loss widens as revenue declines - TradingView
Lipocine posts $2.6 million Q2 net loss as revenue falls - Quiver Quantitative
Lipocine Inc. Q2 2026: Revenue $190099 EPS $(0.32) — 10-Q Summary - TradingView
Lipocine (NASDAQ: LPCN) widens H1 loss but extends cash runway to 2027 - stocktitan.net
Lipocine Appoints Michael J. Grissinger to Board of Directors - Morningstar
Lipocine Appoints Industry Veteran Grissinger to Board - TipRanks
Lipocine appoints Michael Grissinger to board of directors By Investing.com - Investing.com Australia
Lipocine appoints Michael Grissinger to board of directors - Investing.com India
Lipocine Inc. Announces Appointment of Michael J. Grissinger to Board of Directors, Effective August 3, 2026 - marketscreener.com
Lipocine Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Lipocine Inc (LPCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lipocine Inc (LPCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LPCN|Lipocine Inc|Price:2.420|Chg%:+0.065 - TradingKey
Lipocine Inc (LPCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lipocine Inc (LPCN) Income Statement - TradingKey
Lipocine Inc (LPCN) Balance Sheet - TradingKey
Lipocine Inc (LPCN) Cash Flow - TradingKey
Lipocine Inc. (LPCN) Q1 2026 Earnings: EPS Miss Pressures Shares as Pipeline Progress Remains KeyCost Structure Review - Vinanet
LPCN|Lipocine Inc|Price:2.080|Chg%:-0.110 - TradingKey
Lipocine Inc (LPCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lipocine Inc (LPCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lipocine Market Sentiment - Benzinga España
LPCN|Lipocine Inc|Price:2.210|Chg%:-0.020 - TradingKey
Lipocine Q1 2026 Earnings: Losses Slightly Wider Than Expected on No RevenueEPS Growth Report - dars.gov.et
LPCN Q1 2026 Earnings: Larger-than-Anticipated Loss as Development Spending ContinuesEPS Growth Rate - vinanet.vn
Lipocine (LPCN) Faces Slight Pullback Amid Sector VolatilityBear Pennant - dars.gov.et
Lipocine Inc. (LPCN) Holds Near Support After Modest Gain, Resistance in FocusBull Pennant - dars.gov.et
Finanzdaten der Lipocine Inc-Aktie (LPCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lipocine Inc-Aktie (LPCN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Higuchi John W. | Director |
Apr 06 '26 |
Buy |
2.05 |
123,000 |
252,150 |
163,797 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 06 '26 |
Buy |
2.03 |
25,000 |
50,750 |
160,679 |
| Patel Mahesh V. | Chief Executive Officer |
Apr 02 '26 |
Buy |
2.02 |
25,000 |
50,500 |
135,679 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):